US Patent Covering Gene Therapy Drug Candidates for Treatment of Osteoarthritis Issued [ 07 Jun 2019 ]

The U.S. Patent and Trademark Office (USPTO) grants a patent for FX201 (GeneQuine’s former human drug candidate GQ-203, acquired by Flexion Therapeutics, Inc.) and veterinary analogs for treatment of osteoarthritis.

US Patent Covering Gene Therapy Drug Candidates for Treatment of Osteoarthritis Issued

The patent covers composition of matter and method of use of helper-dependent adenoviral vectors expressing interleukin-1 receptor antagonist in the treatment of osteoarthritis. In December of 2017, Flexion Therapeutics Inc. (Nasdaq: FLXN) of Burlington, MA, USA, acquired the global rights to FX201 from GeneQuine Biotherapeutics GmbH for human applications, while GeneQuine retained the rights for veterinary use. Securing patent protection in USA is a major milestone as USA represents the largest market for treatment of osteoarthritis.

Back